Although originally focused more on providers and health tech, the US conference HLTH has been steadily widening its scope and now hosts a wide variety of healthcare stakeholders.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh